Veru announces positive topline data from phase 2b quality clinical study: enobosarm preserved lean mass in patients receiving wegovy® (semaglutide) for weight reduction

-- study met primary endpoint: enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving wegovy (p=0.002) -- -- patients on enobosarm on average lost 71% less lean mass than patients receiving wegovy alone --
VERU Ratings Summary
VERU Quant Ranking